JMCR Family Office

Anji Pharmaceuticals is dedicated to developing innovative metabolic drugs aimed at addressing chronic diseases, including pain, cardiovascular, and cerebrovascular conditions. The company focuses on high-value targets that are validated by human genetics, ensuring that its discovery and clinical efforts are thorough and scientifically grounded. Anji Pharmaceuticals employs a team of skilled scientists and entrepreneurs who are committed to accelerating the development and delivery of effective medical treatments in China and globally. Through its strategic approach and commitment to addressing unmet medical needs, the company seeks to improve patient health outcomes through drug innovation.

Developer and researcher of innovative drugs for vision treatment designed to cure topical diseases. The company focuses on delivering new therapies to millions of patients living with chronic ocular or dermal inflammatory diseases by combining world-class expertise and promising drug targets, providing best-in-class therapeutics and pharmaceuticals for the treatment of dry eye syndromes and atopic dermatitis.

Anji Pharmaceuticals is dedicated to developing innovative metabolic drugs aimed at addressing chronic diseases, including pain, cardiovascular, and cerebrovascular conditions. The company focuses on high-value targets that are validated by human genetics, ensuring that its discovery and clinical efforts are thorough and scientifically grounded. Anji Pharmaceuticals employs a team of skilled scientists and entrepreneurs who are committed to accelerating the development and delivery of effective medical treatments in China and globally. Through its strategic approach and commitment to addressing unmet medical needs, the company seeks to improve patient health outcomes through drug innovation.

Riparian Pharmaceuticals, Inc. is a biotechnology company based in Boston, Massachusetts, focused on discovering innovative therapeutics that address endothelial dysfunction and enhance vascular health. Established in 2012, the company employs advanced models of vascular pathophysiology to develop medical therapies aimed at treating cardiovascular and inflammatory diseases. By targeting new vasoprotective pathways, Riparian Pharmaceuticals seeks to improve endothelial function and reduce vascular complications associated with both common and rare vascular diseases. This approach is designed to enable healthcare providers to achieve better outcomes for their patients.

SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.

Tekeluo Biotech is a Healthcare company.

Anji Pharmaceuticals is dedicated to developing innovative metabolic drugs aimed at addressing chronic diseases, including pain, cardiovascular, and cerebrovascular conditions. The company focuses on high-value targets that are validated by human genetics, ensuring that its discovery and clinical efforts are thorough and scientifically grounded. Anji Pharmaceuticals employs a team of skilled scientists and entrepreneurs who are committed to accelerating the development and delivery of effective medical treatments in China and globally. Through its strategic approach and commitment to addressing unmet medical needs, the company seeks to improve patient health outcomes through drug innovation.

Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company develops structure based drug discovery, fragment based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery platforms. The company’s products include cell lines, crystal structures, GPCR proteins, antibodies, and proteins. It also offers EFS, gene-to-protein and gene-to-structure, viva engine for lead discovery, medicinal chemistry, in vitro pharmacology, and antibody discovery services. Viva Biotech Holdings was founded in 2008 and is headquartered in Shanghai, China.

Mirata Pharmaceuticals is a Plymouth Meeting company working on opioid alternatives for pain relief.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, with its primary products being EB-001A for aesthetic applications and EB-001T for therapeutic purposes. Originally founded as Endurance Biotech in 2015, the company rebranded to Bonti, Inc. in August of the same year. Based in Newport Beach, California, Bonti operates as a subsidiary of Allergan plc as of October 2018. The founding team includes Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, with its primary products being EB-001A for aesthetic applications and EB-001T for therapeutic purposes. Originally founded as Endurance Biotech in 2015, the company rebranded to Bonti, Inc. in August of the same year. Based in Newport Beach, California, Bonti operates as a subsidiary of Allergan plc as of October 2018. The founding team includes Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Dogma Therapeutics is a biotechnology company based in the United States that specializes in developing small molecule inhibitors targeting PCSK9, a protein involved in cholesterol regulation. The firm has successfully identified orally bioavailable small molecule inhibitors that effectively lower blood lipid levels, addressing a significant challenge in the pharmaceutical industry, where previous attempts primarily relied on monoclonal antibodies. Utilizing high-resolution x-ray structures of their compounds bound to PCSK9, Dogma Therapeutics employs structure-based design to achieve high-affinity interactions. This innovative approach aims to transform the treatment landscape for cholesterol management and improve the economic viability of PCSK9-based therapies.

Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.

Developer and researcher of innovative drugs for vision treatment designed to cure topical diseases. The company focuses on delivering new therapies to millions of patients living with chronic ocular or dermal inflammatory diseases by combining world-class expertise and promising drug targets, providing best-in-class therapeutics and pharmaceuticals for the treatment of dry eye syndromes and atopic dermatitis.

Kickback, Co. is a company that specializes in developing products for the esports industry. Founded in December 2014 and based in Sherman Oaks, California, Kickback has created some of the largest online platforms for competitive gaming. Its platform allows gamers to engage in competitive video games while providing the opportunity to earn money. Users can place bets on video games, esports, and traditional casino games, enabling gaming enthusiasts to challenge friends and capitalize on their gaming skills.

Tabomedex Biosciences, Inc. develops inhibitors of molecules for treatment of type two diabetes. It offers allosteric MK2 inhibitors, which ameliorate insulin sensitivity and have robust cardio protective effects. The company was founded in 2017 and is based in Boxford, Massachusetts.

FunPlus is a prominent interactive entertainment company with headquarters in the United States and China, employing over 700 people across eight global offices. The company specializes in the development of popular mobile games and focuses on cross-platform game development and intellectual property creation. FunPlus is also known for its esports division, FunPlus Sports, which manages the world champion League of Legends team FunPlus Phoenix and collaborates with major publishers like Riot Games and Netease to host various esports tournaments. In addition, FunPlus Ventures invests in promising teams within the digital entertainment sector, maintaining an equity portfolio that includes notable companies such as Singularity 6, Cloud9, and thatgamecompany. Through its diverse offerings, FunPlus aims to deliver engaging and innovative gaming experiences to audiences worldwide.

Stripe, Inc. is a global technology company that provides application programming interfaces (APIs) and tools designed to facilitate online payment processing for businesses. Its comprehensive platform includes solutions for payments, subscriptions, fraud detection, and data analytics, among others. Stripe's offerings, such as Stripe Connect for routing payments, Stripe Radar for fraud prevention, and Stripe Checkout for seamless transaction processes, cater to a diverse clientele ranging from startups to established enterprises. The company also addresses financing challenges faced by online businesses through Stripe Capital, which offers fast and flexible funding options. With operations in multiple countries, including the United States, the United Kingdom, and Singapore, Stripe aims to simplify financial infrastructure and support the growth of internet-based businesses, thereby contributing to the overall economic landscape of the digital economy. Founded in 2010 and headquartered in San Francisco, California, Stripe has established partnerships with leading technology firms to enhance its service capabilities.